Report on hearing loss in oncology

Christiane Schultz,Maria Valéria Schmidt Goffi-Gomez,Patrícia Helena Pecora Liberman,André Lopes Carvalho

doi:10.1016/s1808-8694(15)30510-3

Christiane Schultz, Maria Valéria Schmidt Goffi-Gomez + Show 2 more

Open Access

https://doi.org/10.1016/s1808-8694(15)30510-3

Copy DOI

Abstract

SummaryCisplatin is used frequently as an antineoplastic drug in the treatment of many different cancers. However, when used in doses over 360mg/m2, ototoxicity may ensue, resulting in loss of hearing. Criteria for identifying and quantifying hearing loss have been devised.AimTo describe the features of different hearing loss classification systems and to identify their implications and use in oncologic patients.MethodHearing loss was classified in 31 patients before and after chemotherapy, according to different criteria, assessing the sensitivity and specificity of each classification system.ResultsHearing loss results were highly variable (ranging from 29% to 61%). Only 4 of 31 subjects with post-therapy hearing loss were identified by all the methods. A few subjects with hearing loss were classified as normal hearing in some of the criteria. A normal PTA was found in 18 of 31 subjects in the post-treatment evaluation.ConclusionNone of the criteria assesses the complaints of patients. The criteria described in this study were inadequate to identify hearing loss following chemotherapy, requiring additional information for physicians to better understand the hearing losses and their implications for the quality of life of patients.

Highlights

Cisplatin (CDDP) is an antineoplastic drug used often in the treatment of various tumors
Cisplatin ototoxicity is the result of cochlear injury, initially in the vascular striae and the outer hair cells of the basal gyrus, which result in hearing loss at high frequencies (Rademaker et al.[7]; Rybak et al.8)
4 subjects with post-therapy hearing loss were identified by all criteria; 7 subjects had no hearing loss in any of the criteria applied in this study

Summary

Introduction

Cisplatin (CDDP) is an antineoplastic drug used often in the treatment of various tumors. Ototoxicity may ensue when the drug is given at a cumulative dose over 360mg/m2 (Brock et al.[3]; Pedalini et al.[4], Simon et al.[5], Knoll et al.[6]). Cisplatin ototoxicity is the result of cochlear injury, initially in the vascular striae and the outer hair cells of the basal gyrus, which result in hearing loss at high frequencies (Rademaker et al.[7]; Rybak et al.[8]). Continued use of the drug may result in hearing loss at low frequencies (Pedalini et al.[4], Zuur et al.[9]). Detecting and monitoring ototoxicity to initiate preventive measures is one of the methods for avoiding hearing loss

Methods

Results

Discussion

Conclusion